


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Attn: Mail Stop Missing Parts
P.O. Box 1450
Alexandria, VA 22313-1450

On 12-3-04

PATENT
Attorney Docket No.: 021044-005820US
Client Reference No.: P.0128.02.US



TOWNSEND and TOWNSEND and CREW LLP

By: Anna C. Kundel
Anna C. Kundel

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LORENS *et al.*

Application No.: 10/696,909

Filed: October 29, 2003

For: MODULATORS OF
ANGIOGENESIS AND
TUMORIGENESIS

Confirmation No.: 9257

Examiner: Not Yet Assigned

Art Unit: 1642

**REQUEST FOR CORRECTED FILING
RECEIPT**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office for the above-identified application for which issuance of a corrected filing receipt is respectfully requested. The requested corrections are indicated on the Filing Receipt and listed below. Also attached is a Supplemental Application Data Sheet, which reflects these changes.


There is an error in that the "Domestic Priority Data" section should read as follows:

This appln claims benefit of 60/421,989 filed 10/29/2002; and
60/512,251 filed 10/17/2003.

There is also an error on an Applicant's name. The third applicant listed on the filing receipt should be: Annabelle Friera, South San Francisco, CA.

A corrected filing receipt is respectfully requested. Applicants believe no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058


Date: December 2, 2004

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ASP/ack
60369303 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

ASR, SF



021044-005820US

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT.CLMS	IND CLMS
10/696,909	10/29/2003	1642	716	021044-005820US	20	52	4

CONFIRMATION NO. 9257

20350
TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

FILING RECEIPT



OC000000013528124

Date Mailed: 08/13/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James B. Lorens, Bones, NORWAY;
Robert E. Atchison, San Francisco, CA;
Annabelle ~~Anabelle~~ Friera, South San Francisco, CA;
Sacha Holland, San Francisco, CA;

Assignment For Published Patent Application

Rigel Pharmaceuticals, Incorporated, South San Francisco, CA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/421,989 10/29/2002 ; and
60/512,251 filed 10/17/2003.

Foreign Applications

If Required, Foreign Filing License Granted: 08/12/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

JZE

Title

Modulators of angiogenesis and tumorigenesis

Preliminary Class

106

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12; if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).